Apnimed
Phase 3We envision a new era where novel oral therapies simplify treatment and improve oxygenation of people living with obstructive sleep apnea.
Founded
2013
Focus
Small Molecules
About
We envision a new era where novel oral therapies simplify treatment and improve oxygenation of people living with obstructive sleep apnea.
Funding History
3Total raised: $175M
Series C$87.5MSectoral Asset ManagementJan 15, 2023
Series B$74MSectoral Asset ManagementJun 15, 2021
Series A$13.5MMorningside VenturesMay 15, 2018
Company Info
TypePrivate
Founded2013
LocationCambridge, United States
StagePhase 3
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile